Drilldown: Medicines

Other values:

Search

None (42) · Drisdol, Calcidol; also many OTC preparations (1) · DXM (1) · DXO (1) · Many OTC; Rx 50,000 IU also available (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Spravato (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Active metabolite of DXM; NMDA antagonist (1) · Contains salvinorin A (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Very potent 5-HT2A agonist; long duration (1) · '"`UNIQ--vote-0000032A-QINU`"' D3 (cholecalciferol) is more potent at raising serum 25(OH)D per dose; D2 remains widely prescribed in the US Rx 50,000 IU formulation'"`UNIQ--ref-0000032B-QINU`"'. (1) · '"`UNIQ--vote-0000042C-QINU`"' D3 is more potent than D2 at raising and sustaining serum 25(OH)D per dose, and is the more common OTC formulation; D2 remains the dominant Rx 50,000 IU formulation in the US for historical reasons. (1)

None (45) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-0000032C-QINU`"', '"`UNIQ--vote-0000032D-QINU`"', '"`UNIQ--vote-0000032E-QINU`"', '"`UNIQ--vote-0000032F-QINU`"' (1) · '"`UNIQ--vote-0000042D-QINU`"', '"`UNIQ--vote-0000042E-QINU`"', '"`UNIQ--vote-0000042F-QINU`"', '"`UNIQ--vote-00000430-QINU`"' (1)

None (45) · Deficiency: 50,000 IU PO weekly for 8-12 weeks, then maintenance 800-2,000 IU/day; maintenance OTC dosing typically 800-2,000 IU/d (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · Maintenance 800-2,000 IU PO daily; deficiency replacement 50,000 IU PO weekly for 8-12 weeks then maintenance, or equivalent daily dosing 5,000-10,000 IU/d (1)

None (45) · 28 mg/device (each dose uses 2 devices) (1) · 50,000 IU capsules (Rx); 8,000 IU/mL oral solution (Rx); 400-5,000 IU OTC tablets and softgels (1) · OTC 400, 1,000, 2,000, 5,000 IU softgels and tablets; Rx 50,000 IU capsules; liquid drops 400-2,000 IU/drop (1)

None (45) · 84 mg per session (1) · No strict; Institute of Medicine UL 4,000 IU/d in adults for chronic use (1) · Not strictly fixed; long-term Upper Limit ~4,000 IU/d in adults (Institute of Medicine) (1)

None (44) · for severe malabsorption) (1) · IM (rare (1) · insufflated (1) · Intranasal (under direct medical supervision) (1) · Oral (3) · PR (1)

None (44) · 45-75 min (oral) (1) · Days to weeks to raise 25(OH)D; clinical effect on bone over months (1) · Weeks to raise 25(OH)D into reference range (1) · Within hours of first administration (1)

None (44) · 4-8 h (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Long; fat-soluble storage in adipose (1) · Long; fat-soluble, stored in adipose (1)

None (44) · Not well characterized (1) · ~24 hours (parent); ~15 days (25(OH)D); 25(OH)D stores persist for months'"`UNIQ--ref-00000330-QINU`"' (1) · ~24 hours (parent); ~15 days (25(OH)D); tissue stores months (1) · ~7-12 hours (1)

None (44) · Not well characterized (1) · ~48% intranasal (1) · ~75% (oral; absorption improved with fat-containing meal) (1) · ~75% (oral; fat-soluble, absorption requires intact biliary/lipid digestion)'"`UNIQ--ref-00000331-QINU`"' (1)

None (44) · Avoid; may cause fetal harm (1) · Not established (1) · Safe at replacement doses; deficiency is itself a risk in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2)

None (44) · OTC (low-dose) and [[USLegal:Prescription only|Rx-only]] (50,000 IU and concentrated solutions) in US (1) · OTC (most) and [[USLegal:Prescription only|Rx-only]] (50,000 IU) in US (1) · Rx, Schedule III (US). REMS program required. (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)